Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment

[1]  H. Baba,et al.  PD-L1 Expression, Tumor-infiltrating Lymphocytes, and Clinical Outcome in Patients With Surgically Resected Esophageal Cancer , 2017, Annals of surgery.

[2]  Qian Chu,et al.  The role of neoantigen in immune checkpoint blockade therapy , 2018, Experimental Hematology & Oncology.

[3]  E. Schmidt.  Developing combination strategies using PD-1 checkpoint inhibitors to treat cancer , 2018, Seminars in Immunopathology.

[4]  X. Yi,et al.  Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study , 2018, Clinical Cancer Research.

[5]  H. Wada,et al.  Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment , 2018, Journal of Immunotherapy for Cancer.

[6]  R. Ganss,et al.  Immunomodulation of Tumor Vessels: It Takes Two to Tango. , 2018, Trends in immunology.

[7]  Florence T. H. Wu,et al.  Pre- and post-operative anti-PD-L1 plus anti-angiogenic therapies in mouse breast or renal cancer models of micro- or macro-metastatic disease , 2018, British Journal of Cancer.

[8]  Kongming Wu,et al.  Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors , 2018, Molecular cancer.

[9]  Xu Wang,et al.  Targeting the IDO1 pathway in cancer: from bench to bedside , 2018, Journal of Hematology & Oncology.

[10]  M. Odenthal,et al.  Combined VEGF and PD-L1 Blockade Displays Synergistic Treatment Effects in an Autochthonous Mouse Model of Small Cell Lung Cancer. , 2018, Cancer research.

[11]  K. Ward,et al.  Atezolizumab for the First-Line Treatment of Non-small Cell Lung Cancer (NSCLC): Current Status and Future Prospects , 2018, Front. Oncol..

[12]  Federico Cappuzzo,et al.  Atezolizumab for First‐Line Treatment of Metastatic Nonsquamous NSCLC , 2018, The New England journal of medicine.

[13]  Angela E. Leek,et al.  Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies , 2018, Cancer cell.

[14]  J. Larkin,et al.  Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial. , 2018, The Lancet. Oncology.

[15]  Dai Fukumura,et al.  Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges , 2018, Nature Reviews Clinical Oncology.

[16]  C. Shao,et al.  Lessons learned from the blockade of immune checkpoints in cancer immunotherapy , 2018, Journal of Hematology & Oncology.

[17]  Betty Y. S. Kim,et al.  Improving immune–vascular crosstalk for cancer immunotherapy , 2018, Nature Reviews Immunology.

[18]  Y. Lou,et al.  Cancer immunotherapy beyond immune checkpoint inhibitors , 2018, Journal of Hematology & Oncology.

[19]  D. Pinato,et al.  PD-L1 , 2017, Journal of Clinical Pathology.

[20]  R. Raman,et al.  Prevention of Age‐Related Macular Degeneration , 2017, Asia-Pacific journal of ophthalmology.

[21]  T. Das,et al.  Intravitreal Ziv‐Aflibercept: Clinical Effects and Economic Impact , 2017, Asia-Pacific journal of ophthalmology.

[22]  Yongchang Zheng,et al.  PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy , 2017, Journal of Hematology & Oncology.

[23]  Bruno Larrivée,et al.  Tumor angiogenesis and vascular normalization: alternative therapeutic targets , 2017, Angiogenesis.

[24]  M. Kudo,et al.  Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial , 2017, The Lancet.

[25]  R. Ronca,et al.  Tumor angiogenesis revisited: Regulators and clinical implications , 2017, Medicinal research reviews.

[26]  A. Giobbie-Hurder,et al.  Combined Anti-VEGF and Anti–CTLA-4 Therapy Elicits Humoral Immunity to Galectin-1 Which Is Associated with Favorable Clinical Outcomes , 2017, Cancer Immunology Research.

[27]  R. Weichselbaum,et al.  Tumour ischaemia by interferon-γ resembles physiological blood vessel regression , 2017, Nature.

[28]  T. Burns,et al.  The next generation of immunotherapy: keeping lung cancer in check , 2017, Journal of Hematology & Oncology.

[29]  D. Hanahan,et al.  Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation , 2017, Science Translational Medicine.

[30]  Y. Kienast,et al.  Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade , 2017, Science Translational Medicine.

[31]  A. Griffioen,et al.  Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy? , 2017, Angiogenesis.

[32]  F. Stossi,et al.  Mutual Regulation of Tumour Vessel Normalization and Immunostimulatory Reprogramming , 2017, Nature.

[33]  A. Ager.  High Endothelial Venules and Other Blood Vessels: Critical Regulators of Lymphoid Organ Development and Function , 2017, Front. Immunol..

[34]  R. Yuan,et al.  PD-1, PD-L1 (B7-H1) and Tumor-Site Immune Modulation Therapy: The Historical Perspective , 2017, Journal of Hematology & Oncology.

[35]  S. Burbidge,et al.  The brain-penetrating CXCR4 antagonist, PRX177561, increases the antitumor effects of bevacizumab and sunitinib in preclinical models of human glioblastoma , 2017, Journal of Hematology & Oncology.

[36]  R. Figlin,et al.  Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma. , 2017, The oncologist.

[37]  A. Giobbie-Hurder,et al.  Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy , 2016, Cancer Immunology Research.

[38]  J. Mercer,et al.  VEGF induces signalling and angiogenesis by directing VEGFR2 internalisation through macropinocytosis , 2016, Journal of Cell Science.

[39]  A. Nakagawara,et al.  Protein glycosylation in cancers and its potential therapeutic applications in neuroblastoma , 2016, Journal of Hematology & Oncology.

[40]  P. Hegde,et al.  Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  Rajesh Raju,et al.  VEGF-A/VEGFR2 signaling network in endothelial cells relevant to angiogenesis , 2016, Journal of Cell Communication and Signaling.

[42]  Suzanne F. Jones,et al.  Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma , 2016, Nature Communications.

[43]  A. Giobbie-Hurder,et al.  VEGF Neutralization Plus CTLA-4 Blockade Alters Soluble and Cellular Factors Associated with Enhancing Lymphocyte Infiltration and Humoral Recognition in Melanoma , 2016, Cancer Immunology Research.

[44]  N. Matsumura,et al.  Expression of Vascular Endothelial Growth Factor in Ovarian Cancer Inhibits Tumor Immunity through the Accumulation of Myeloid-Derived Suppressor Cells , 2016, Clinical Cancer Research.

[45]  Weilan Ye,et al.  The Complexity of Translating Anti-angiogenesis Therapy from Basic Science to the Clinic. , 2016, Developmental cell.

[46]  P. Hegde,et al.  The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition , 2016, Clinical Cancer Research.

[47]  B. Neyns,et al.  Combined VEGFR and CTLA-4 blockade increases the antigen-presenting function of intratumoral DCs and reduces the suppressive capacity of intratumoral MDSCs. , 2016, American journal of cancer research.

[48]  G. Keating.  Axitinib: A Review in Advanced Renal Cell Carcinoma , 2015, Drugs.

[49]  J. Wolchok,et al.  Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[50]  B. Slotman,et al.  Combining radiotherapy with sunitinib: lessons (to be) learned , 2015, Angiogenesis.

[51]  Antoni Ribas,et al.  Classifying Cancers Based on T-cell Infiltration and PD-L1. , 2015, Cancer research.

[52]  M. May,et al.  Understanding high endothelial venules: Lessons for cancer immunology , 2015, Oncoimmunology.

[53]  C. Meyer,et al.  Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients , 2015, Proceedings of the National Academy of Sciences.

[54]  G. Coukos,et al.  Targeting the tumor vasculature to enhance T cell activity , 2015, Current opinion in immunology.

[55]  E. Tartour,et al.  VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors , 2015, The Journal of experimental medicine.

[56]  R. Jain,et al.  Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. , 2014, Cancer cell.

[57]  G. Keating.  Bevacizumab: A Review of Its Use in Advanced Cancer , 2014, Drugs.

[58]  I. Keklikoglou,et al.  Role of angiopoietin-2 in adaptive tumor resistance to VEGF signaling blockade. , 2014, Cell reports.

[59]  S. Quezada,et al.  Impact of tumour microenvironment and Fc receptors on the activity of immunomodulatory antibodies. , 2014, Trends in immunology.

[60]  P. Dessen,et al.  PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation , 2014, The Journal of experimental medicine.

[61]  G. Coukos,et al.  Tumor Endothelium FasL Establishes a Selective Immune Barrier Promoting Tolerance in Tumors , 2014, Nature Medicine.

[62]  G. Coukos,et al.  T-cell and NK-cell infiltration into solid tumors: a key limiting factor for efficacious cancer immunotherapy. , 2014, Cancer discovery.

[63]  A. D. Van den Abbeele,et al.  Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma , 2014, Cancer Immunology Research.

[64]  E. Raymond,et al.  Unraveling galectin-1 as a novel therapeutic target for cancer. , 2014, Cancer treatment reviews.

[65]  Gabriel A. Rabinovich,et al.  Glycosylation-Dependent Lectin-Receptor Interactions Preserve Angiogenesis in Anti-VEGF Refractory Tumors , 2014, Cell.

[66]  Lauri Eklund,et al.  Tie1 deletion inhibits tumor growth and improves angiopoietin antagonist therapy. , 2014, The Journal of clinical investigation.

[67]  M. Shibuya.  VEGFR and type-V RTK activation and signaling. , 2013, Cold Spring Harbor perspectives in biology.

[68]  I. Mellman,et al.  Oncology meets immunology: the cancer-immunity cycle. , 2013, Immunity.

[69]  H. Yoshiji,et al.  Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti‐tumour effect in vivo , 2013, Clinical and experimental immunology.

[70]  D. McEwen,et al.  Development and characterization of a high-throughput in vitro cord formation model insensitive to VEGF inhibition , 2013, Journal of Hematology & Oncology.

[71]  Dai Fukumura,et al.  Vascular normalization as an emerging strategy to enhance cancer immunotherapy. , 2013, Cancer research.

[72]  Yan Zheng,et al.  Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. , 2013, Current opinion in immunology.

[73]  L. Claesson‐Welsh,et al.  VEGFA and tumour angiogenesis , 2013, Journal of internal medicine.

[74]  Weijing Sun,et al.  Angiogenesis in metastatic colorectal cancer and the benefits of targeted therapy , 2012, Journal of Hematology & Oncology.

[75]  R. Jain,et al.  Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy , 2012, Proceedings of the National Academy of Sciences.

[76]  V. Boussiotis,et al.  Selective Effects of PD-1 on Akt and Ras Pathways Regulate Molecular Components of the Cell Cycle and Inhibit T Cell Proliferation , 2012, Science Signaling.

[77]  C. Drake,et al.  Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. , 2012, Current opinion in immunology.

[78]  S. Rosenberg,et al.  Local Delivery of lnterleukin-12 Using T Cells Targeting VEGF Receptor-2 Eradicates Multiple Vascularized Tumors in Mice , 2012, Clinical Cancer Research.

[79]  Zainab N. Khan,et al.  Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway. , 2012, Cancer cell.

[80]  C. Drake,et al.  Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma , 2011, Clinical Cancer Research.

[81]  Lin Zhang,et al.  Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells , 2011, Nature.

[82]  S. Barry,et al.  An Antibody Targeted to VEGFR-2 Ig Domains 4-7 Inhibits VEGFR-2 Activation and VEGFR-2–Dependent Angiogenesis without Affecting Ligand Binding , 2011, Molecular Cancer Therapeutics.

[83]  M. Miyasaka,et al.  Neogenesis and development of the high endothelial venules that mediate lymphocyte trafficking , 2010, Cancer science.

[84]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[85]  P. De Baetselier,et al.  Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. , 2010, Cancer research.

[86]  John M L Ebos,et al.  Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. , 2009, Cancer cell.

[87]  Masahiro Inoue,et al.  Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. , 2009, Cancer cell.

[88]  Dieter Häussinger,et al.  Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.

[89]  Robert S Kerbel.  Tumor angiogenesis. , 2008, The New England journal of medicine.

[90]  D. Carbone,et al.  Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF. , 2007, Blood.

[91]  G. Meinhardt,et al.  Vatalanib: the clinical development of a tyrosine kinase inhibitor of angiogenesis in solid tumours , 2007, Expert opinion on investigational drugs.

[92]  A. Bikfalvi,et al.  Tumor angiogenesis , 2020, Advances in cancer research.

[93]  R. Jain.  Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy , 2005, Science.

[94]  George Coukos,et al.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.

[95]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[96]  Seth M Steinberg,et al.  A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. , 2003, The New England journal of medicine.

[97]  Rakesh K Jain,et al.  Molecular regulation of vessel maturation , 2003, Nature Medicine.

[98]  Yasufumi Sato,et al.  Molecular diagnosis of tumor angiogenesis and anti-angiogenic cancer therapy , 2003, International Journal of Clinical Oncology.

[99]  H. Dvorak.  Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[100]  D. Pode,et al.  Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. , 1999, The Journal of clinical investigation.

[101]  D. Carbone,et al.  Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells , 1996, Nature Medicine.

[102]  D. Carbone,et al.  Erratum: Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells (Nature Medicine 2, 1096-1103 (1996)) , 1996 .

[103]  J. Folkman.  Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.

[104]  J Folkman,et al.  Transplacental carcinogenesis by stilbestrol. , 1971, The New England journal of medicine.

[105]  Michael Schwenk,et al.  Tumor , 1828, The London medical and physical journal.